Results with ZILBRYSQ

Significant improvements in the activities of daily living

ZILBRYSQ significantly improved activities of daily living such as breathing, talking, swallowing, and being able to rise from a chair.*

*As determined by improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline on Week 12 of the study; -4.4 points in the ZILBRYSQ-treated group (86 people) vs -2.3 in the placebo group (88 people).

Rapid improvements in daily living

ZILBRYSQ was shown to significantly improve activities of daily living at 12 weeks. Improvements were seen in some participants as early as Week 1.

More than 7 in 10 participants responded to treatment

Among clinical trial participants receiving ZILBRYSQ, a majority experienced improvements in symptoms.^†

^†73% (63 out of 86 people) in the 0.3 mg/kg group compared to 46% (40 out of 88 people) in the placebo group, as determined by improvement in MG-ADL score from baseline without rescue therapy on Week 12 of study. Response was defined as at least a 3-point improvement in MG-ADL score from baseline without rescue therapy by Week 12.

Nearly 6 in 10 participants saw improvement in muscle strength

58% (50 out of 86 people) of clinical trial participants receiving ZILBRYSQ experienced reduced muscle weakness at 12 weeks, improving their physical functions.^‡

^‡Compared to 33% of people taking placebo, as determined by the Quantitative MG (QMG) total score. The QMG score assesses muscle weakness based on 13 physical functions, including looking side-to-side, looking upward, facial movements, swallowing, speaking, outstretching right arm, outstretching left arm, vital capacity, right hand grip, left hand grip, lifting head, outstretching right leg, and outstretching left leg. Response is defined as having at least a 5-point decrease in QMG score at Week 12 without rescue therapy.